Fixed dose RAI therapy is very much cost effective mode of treatment for primary hyperthyroidism with ~89% success by giving single dose.
INTRODUCTION
Hyperthyroidism is a common endocrine disorder worldwide with prevalence of 2:1000 in iodine sufficient area (1) . The modes of treatment available are antithyroid drugs, surgery and radioiodine therapy (1) . At NINMAS, Radioactive iodine (RAI) therapy by 131I for hyperthyroidism was first introduced in 1980. Initially for long years calculated dose of RAI was used to treat the primary hyperthyroid calculating thyroid gland size and radio-iodine uptake. Then a protocol was developed in 2002 on fixed dose of RAI therapy through a national workshop on the basis of consensus of nuclear medicine specialists, endocrinologists, medicine specialist and ENT surgeons. Since then the fixed dose RAI therapy had been practiced at thyroid division, NINMAS. The guidelines were upgraded in 2015(2).
The objectives of this study was to evaluate the fixed dose RAI therapy in hyperthyroid patients referred to NINMAS according to guidelines for hyperthyroid patients by the Society of Nuclear Medicine, Bangladesh (3). In this study, a total 1349 hyperthyroid patients were evaluated at different time period of follow up from 1 to 5 years after fixed dose RAI. According to Society of Nuclear Medicine Bangladesh (SNMB) protocol 2002, the modified fixed doses of radioiodine in different types of hyperthyroidism are as follows: for Graves' disease: 3-15 mCi; for multinodular goiter: 20-30 mCi and for toxic nodule: 15-25 mCi (3). After radio-iodine therapy, patients were first followed up after 2 months, then 3monthly at first year and subsequently 6 monthly up to 5 years. Outcome of radioiodine treatment was considered as success when patients become euthyroid or hypothyroid. Failure of RAI treatment was considered when patients remained hyperthyroid after six months of therapy.
PATIENTS AND METHODS
Hyperthyroid state was declared as when FT3, FT4 level were greater than normal and TSH level less than 0.3mIU/L. In most of the cases increased diffuse accumulation of Tc-99m was seen on thyroid scan and I-131 uptake more than 10% in 2 hours and more than 25% in 24 hours were found. Hypothyroid condition was considered when TSH level > 5 mIU/L and FT3
and FT4 level were less than normal. Patients who developed hypothyroidism were given levothyroxine replacement therapy. In cases of persisting hyperthyroidism, second dose of RAI therapy in higher dose was given after six months. Data were expressed in number and percentages.
RESULTS
The demographic information of the hyperthyroid patients with the age of the patients, disease profile, number of dose taken, amount of dose intake in treatment and according to sex distribution were shown in Table-1 and Table 2 showed treatment outcome. 
DISCUSSION
Radioiodine therapy for hyperthyroidism was first introduced at our institute in the year of 1980. Medical records of all patients after RAI therapy had been archived and followed up by thyroid division of this institute. Initially calculated dose of RAI was used and fixed dose RAI therapy had been practiced since 2002. In the present study, we analyzed outcome of fixed dose RAI therapy in1349 primary hyperthyroid patients. Other authors also mentioned that the fixed dose method is simpler and more costeffective for Graves' disease, toxic multinodular goiter and toxic adenoma (4).
In this study, diffuse toxic goiter (Graves' disease) was found the commonest cause followed by toxic multinodular goiters which are comparable to other reported studies (3, 5) . Female predominance of hyperthyroidism was noticed in the presented study which was similar to other studies (5).
This institute is a tertiary referral hospital. Patients are referred to this institute from all over the country. We chose fixed and comparatively higher dose for all the patients because the cure rate is > 90% whereas low dose is more likely to cause treatment failure (6) . Persistent or recurrent hyperthyroidism after radioiodine treatment is not uncommon and it usually required re-treatment. Failure of RAI therapy was defined as receipt of additional doses of radioiodine. Successful or failed treatment of hyperthyroidism was evaluated on thyroid function studies at defined time periods after radioiodine treatment. Resistant cases after first dose of radioactive treatment were seen in 152 patients (11.26%), who remained hyperthyroid six months after treatment. Second dose of radioiodine therapy could be given in 138 patients and rest 14 patients were on antithyroid drugs. After second dose, 31 patients (22.46%) required 3rd dose and 39 patients (28.26%) required more than three doses.
In other studies, persistent or recurrent hyperthyroidism occurs in 21%-29% of patients treated with conventional doses of radioactive iodine (7). Lower persistent or recurrent hyperthyroidism rates are achievable with higher doses of radioiodine therapy. In other hand, higher treatment doses increase the adverse radiation effects. The persistent hyperthyroidism after I-131 therapy is still a therapeutic problem. Multiple doses of RAI resulted to 100% cure of hyperthyroidism but in the majority of these patients, hypothyroidism is the resulting adverse effect (8) . Hyperthyroidism was treated at the cost of hypothyroidism. Hypothyroidism is acceptable than hyperthyroidism because it is easy to treat under physician's control. In our study the persistent hyperthyroidism is higher in diffuse toxic goiter than in multinodular goiter or single toxic nodular goiter resulting 56.52 %, 39.13%, 4.34%
These results are also similar to the data reported by the earlier mentioned author (8) .
Antithyroid drugs have been reported to modify the response to radio-iodine through an ill-defined mechanism of radiation resistance. It has also been observed that antithyroid drugs started within 8 days after radioiodine treatment produce less frequent hypothyroidism but a reciprocal increase in persistent hyperthyroidism (9) . In this study, we have given antithyroid medication to all our patients 2 days prior and after radioiodine therapy upto one month.
In a study by Allahabadia et al. (10) which included 813 patients, the authors found that male patients with large goiter are more likely not to respond to single dose of 131I even with doses of 370 MBq. Male patients had a significantly worse outcome after treatment than females, despite a reduced prevalence of palpable goiter in males. This observation was even more marked in those with Grave's disease, where the cure rate with a single dose of radioiodine was only 50 % (10) . But this finding is discordant with our results. In present study, female predominance (62.31%) was found in treatment failure group.
Limitations of this study are retrospective nature of study. The factors responsible for radiation resistant to thyroid gland are not analyzed in this study. 
CONCLUSION

